BrightHeart
31.5.2023 10:01:39 CEST | ACCESS Newswire | Press release
PARIS, FRANCE / ACCESSWIRE / May 31, 2023 / BrightHeart, a Paris-based medical technology company developing unique artificial intelligence software focused on improving the detection of congenital heart defects in fetuses, announced today that it has raised €2 million in seed financing from Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London, and Milan. The funds are being deployed to bolster the development of the BrightHeart technology, prepare its regulatory submission(s), and facilitate the company's expansion.
Combined with unique access to a proprietary database of more than 20,000 fetal ultrasound exams, BrightHeart's innovative technology leverages AI and top-level expertise in fetal ultrasound cardiac imaging to help caregivers improve the detection of complex fetal heart defects in utero, during an ultrasound screening exam, when early interventions could either correct them or greatly improve a child's chance of survival. This is the fourth investment by Sofinnova's medtech acceleration fund, Sofinnova MD Start III.
Cécile Dupont, BrightHeart's Chief Executive Officer and Partner at Sofinnova Partners, said:" Fetal ultrasound screening of the heart is universally recommended during pregnancy. Prenatal diagnosis of fetal heart defects can significantly improve newborn outcomes, but in practice, as few as 30% are detected. BrightHeart's unique, AI-powered approach has the potential to revolutionize screening for congenital heart defects by supporting clinicians with a real-time, expert-level interpretation of one of the most complex exams in the ultrasound practice."
BrightHeart has already brought together an experienced team in the fields of fetal cardiology, AI, and software development. This unique group is led by Chief Technology Officer Christophe Gardella, an accomplished data scientist and leader with extensive experience in the development of AI-powered medtech solutions who directed the algorithm efforts at Cardiologs.
Inspired by the company's mission, the multidisciplinary team has made remarkable progress. Just a few months after its inception, the company is already finalizing a first version of its software, filed multiple patent applications in Europe and the U.S., engaged with regulators, and is actively working on the preparation of regulatory submissions for its first product in key geographies.
BrightHeart builds on an idea by Dr. Marilyne Levy and Dr. Bertand Stos, BrightHeart co-founders, fetal cardiologists, and leading experts in the sector. They bring a world-class expertise to the project as well as a large, qualified database of fetal heart ultrasound exams.
In a joint statement, Drs. Levy and Stos said: "BrightHeart's innovative approach addresses a major critical need. We are thrilled to count on operational, strategic, and financial support from Sofinnova MD Start III in this important commitment to accelerate the deployment of our technology in the clinic, and to improve maternal and fetal health."
About BrightHeart
BrightHeart SAS is a Paris-based, privately held, pre-clinical medical device company and part of Sofinnova MD Start, the venture capital firm's medical device accelerator. The company's software leverages the power of artificial intelligence to analyze fetal heart ultrasound exams and support clinicians with the prenatal identification of congenital heart defects. The technology aims to improve newborn outcomes by anticipating delivery care and early intervention.
BrightHeart builds on an idea by Dr. Marilyne Levy and Dr. Bertand Stos, two leading fetal cardiologists based in Paris, France.
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical, and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future.
Founded in 1972, Sofinnova Partners is a deeply established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2.5 billion under management. For more information, please visit: www.sofinnovapartners.com.
For further information:
Cécile Dupont
Chief Executive Officer, BrightHeart
cecile@brightheart.fr
SOURCE: BrightHeart
View source version on accesswire.com:
https://www.accesswire.com/758073/BrightHeart-Announces-2-Million-in-Seed-Financing-from-Sofinnova-Partners-to-Improve-the-Detection-of-Fetal-Heart-Abnormalities
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Surmodics Opens Medical Device Coating Capabilities in Ireland10.9.2026 16:00:00 CEST | Press release
The Galway Facility Brings Nearly 50 Years of Coating Expertise, Cleanroom Coating Services and Analytical Testing Closer to Medical Device Manufacturers Across Ireland and Europe BALLINASLOE, COUNTY GALWAY, IRELAND / ACCESS Newswire / September 10, 2026 / Surmodics, Inc. today announced its expanded medical device coating capabilities in Galway, Ireland, expanding access to the company's Performance Coatings and coating services for medical device manufacturers throughout Ireland and Europe. The facility now includes dedicated cleanroom environments designed for medical device coating services and brings Surmodics' nearly 50 years of coating experience closer to one of the world's leading medical technology hubs. "Ireland is home to a significant concentration of medical device manufacturers and technology innovators, making it an important market for Surmodics and our customers," said Damien Kilcommons, Vice President of Site Operation at the Ireland facility. "By establishing dedica
MicroVision to Preview Next-Generation Lidar-Based Perception Platform at IAA Transportation 202610.9.2026 15:20:00 CEST | Press release
New modular approach will bring together MicroVision lidar hardware, perception software and open sensor integration to enable flexible perception solutions across applications REDMOND, WA AND HANOVER, GER / ACCESS Newswire / September 10, 2026 / MicroVision, Inc. (NASDAQ:MVIS), a leader in advanced perception technologies, today announced plans to unveil its MicroVision Perception Platform™ at IAA Transportation 2026 in Hanover, Germany next week, marking the next evolution of the company's Lidar 2.0 strategy. The new modular platform is designed to bring together MicroVision's expanding portfolio of lidar hardware, perception software and open sensor integration into a flexible architecture that can be configured around the requirements of individual applications spanning automotive, commercial vehicles, industrial, security, defense and aerial use cases. Rather than relying on a fixed sensor configuration or closed "black box" solution, the MicroVision Perception Platform is being d
GA-ASI Unveils Wildfire UAS for Military, Civil and Commercial Roles10.9.2026 15:00:00 CEST | Press release
New Uncrewed Aircraft Combines Exceptional Endurance and Range with Unsurpassed Payload and Affordability at Scale SAN DIEGO, CA / ACCESS Newswire / September 10, 2026 / The world leader in Uncrewed Aircraft Systems, General Atomics Aeronautical Systems, Inc. (GA-ASI) is pleased to announce its groundbreaking Wildfire UAS, a clean-sheet aircraft designed to maximize future investments in large uncrewed aircraft that incorporates lessons learned over decades of large-scale global UAS operations. Wildfire draws upon more than 30 years of delivering more than 1,600 world-changing uncrewed aircraft, including the MQ-1B Predator®, MQ-9A Reaper®, MQ-9B SkyGuardian®, MQ-20 Avenger® and FQ-42A Collaborative Combat Aircraft. GA-ASI aircraft have amassed nearly 10 million total flight hours, mostly in combat, and introduced many of the technologies and concepts now emulated by others around the world. "This is exactly the right design for high-demand missions and cost-conscious customers," said
Steelcase Names Proven Growth Leader Irene Tasi as President9.9.2026 21:00:00 CEST | Press release
Experienced commercial and innovative leader will guide the Steelcase business as the company builds on its design leadership, dealer network and customer-focused strategy. GRAND RAPIDS, MI / ACCESS Newswire / September 9, 2026 / Steelcase today announced Irene Tasi has been named president of Steelcase and will lead the business effective September 14, 2026. Tasi brings more than 25 years of executive leadership experience with a track record leading complex businesses through growth, portfolio development, commercial execution, and organizational change. Her background includes full P&L responsibility, enterprise strategy, innovation, and sales and channel leadership. She will report to Jeff Lorenger, Chairman, President and Chief Executive Officer, HNI Corporation. "Irene brings a combination of commercial leadership, product innovation, operating discipline, and customer focus that makes her exceptionally well-suited to lead Steelcase," said Lorenger. "She has led businesses where
Global Study: Nursing Shortages Require Workforce Policy Solutions, Not Recruitment Campaigns Alone9.9.2026 15:01:00 CEST | Press release
Why people choose nursing, and why they leave, comes down to the same factors PHILADELPHIA, PA / ACCESS Newswire / September 9, 2026 / The global nursing shortage cannot be solved simply by encouraging more people to enter the profession, according to a new evidence brief from the Global Nursing Workforce Centre (GNWC), a joint initiative of the International Council of Nurses (ICN) and TruMerit®. Drawing on research from 42 countries, the brief, The Attractiveness of Nursing for Prospective and Current Nursing Students, finds that the factors influencing people to choose nursing are often the same ones that determine whether they stay. Working conditions, compensation, professional respect, career development opportunities, workplace experiences, and the ability to provide quality care all shape nursing attractiveness to current nurses as well as potential recruits. The findings suggest that countries seeking to strengthen their nursing workforce must focus not only on recruitment, bu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom